Replies to post #59678 on Biotech Values

[exwannabe]

I don't buy the MNTA story from briefing.

It is absurd that the stock would move this heavy on a completety meaningless remark.

Question, could some fund/institution/etc. think MNTA could profit (future or course) from a permanent impairment to the raw heparin supply (triggered by the NY times artical that was REALLY scary if you understand the Chinease supply chain)?

I don't see why this would be the case, but sometimes the financial guys don't follow details that well.

[ThomasS]

MNTA: IMO, I suspect (based on Craig Wheeler's remarks), that the final path forward will be determined by MNTA and PR'd for investors within the next 4 weeks or so.